Cargando…

Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer’s Disease

Substantial evidence in the literature demonstrates the pleiotropic effects of the administration of recombinant human erythropoietin (rhEPO) and its molecular variants in different tissues and organs, including the brain. Some of these reports suggest that the chemical properties of this molecule b...

Descripción completa

Detalles Bibliográficos
Autores principales: Jarero-Basulto, José J., Rivera-Cervantes, Martha C., Gasca-Martínez, Deisy, García-Sierra, Francisco, Gasca-Martínez, Yadira, Beas-Zárate, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760199/
https://www.ncbi.nlm.nih.gov/pubmed/33255969
http://dx.doi.org/10.3390/ph13120424
_version_ 1783627276670205952
author Jarero-Basulto, José J.
Rivera-Cervantes, Martha C.
Gasca-Martínez, Deisy
García-Sierra, Francisco
Gasca-Martínez, Yadira
Beas-Zárate, Carlos
author_facet Jarero-Basulto, José J.
Rivera-Cervantes, Martha C.
Gasca-Martínez, Deisy
García-Sierra, Francisco
Gasca-Martínez, Yadira
Beas-Zárate, Carlos
author_sort Jarero-Basulto, José J.
collection PubMed
description Substantial evidence in the literature demonstrates the pleiotropic effects of the administration of recombinant human erythropoietin (rhEPO) and its molecular variants in different tissues and organs, including the brain. Some of these reports suggest that the chemical properties of this molecule by itself or in combination with other agents (e.g., growth factors) could provide the necessary pharmacological characteristics to be considered a potential protective agent in neurological disorders such as Alzheimer’s disease (AD). AD is a degenerative disorder of the brain, characterized by an aberrant accumulation of amyloid β (Aβ) and hyperphosphorylated tau (tau-p) proteins in the extracellular and intracellular space, respectively, leading to inflammation, oxidative stress, excitotoxicity, and other neuronal alterations that compromise cell viability, causing neurodegeneration in the hippocampus and the cerebral cortex. Unfortunately, to date, it lacks an effective therapeutic strategy for its treatment. Therefore, in this review, we analyze the evidence regarding the effects of exogenous EPOs (rhEPO and its molecular variants) in several in vivo and in vitro Aβ and tau-p models of AD-type neurodegeneration, to be considered as an alternative protective treatment to this condition. Particularly, we focus on analyzing the differential effect of molecular variants of rhEPO when changes in doses, route of administration, duration of treatment or application times, are evaluated for the improved cellular alterations generated in this disease. This narrative review shows the evidence of the effectiveness of the exogenous EPOs as potential therapeutic molecules, focused on the mechanisms that establish cellular damage and clinical manifestation in the AD.
format Online
Article
Text
id pubmed-7760199
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77601992020-12-26 Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer’s Disease Jarero-Basulto, José J. Rivera-Cervantes, Martha C. Gasca-Martínez, Deisy García-Sierra, Francisco Gasca-Martínez, Yadira Beas-Zárate, Carlos Pharmaceuticals (Basel) Review Substantial evidence in the literature demonstrates the pleiotropic effects of the administration of recombinant human erythropoietin (rhEPO) and its molecular variants in different tissues and organs, including the brain. Some of these reports suggest that the chemical properties of this molecule by itself or in combination with other agents (e.g., growth factors) could provide the necessary pharmacological characteristics to be considered a potential protective agent in neurological disorders such as Alzheimer’s disease (AD). AD is a degenerative disorder of the brain, characterized by an aberrant accumulation of amyloid β (Aβ) and hyperphosphorylated tau (tau-p) proteins in the extracellular and intracellular space, respectively, leading to inflammation, oxidative stress, excitotoxicity, and other neuronal alterations that compromise cell viability, causing neurodegeneration in the hippocampus and the cerebral cortex. Unfortunately, to date, it lacks an effective therapeutic strategy for its treatment. Therefore, in this review, we analyze the evidence regarding the effects of exogenous EPOs (rhEPO and its molecular variants) in several in vivo and in vitro Aβ and tau-p models of AD-type neurodegeneration, to be considered as an alternative protective treatment to this condition. Particularly, we focus on analyzing the differential effect of molecular variants of rhEPO when changes in doses, route of administration, duration of treatment or application times, are evaluated for the improved cellular alterations generated in this disease. This narrative review shows the evidence of the effectiveness of the exogenous EPOs as potential therapeutic molecules, focused on the mechanisms that establish cellular damage and clinical manifestation in the AD. MDPI 2020-11-26 /pmc/articles/PMC7760199/ /pubmed/33255969 http://dx.doi.org/10.3390/ph13120424 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Jarero-Basulto, José J.
Rivera-Cervantes, Martha C.
Gasca-Martínez, Deisy
García-Sierra, Francisco
Gasca-Martínez, Yadira
Beas-Zárate, Carlos
Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer’s Disease
title Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer’s Disease
title_full Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer’s Disease
title_fullStr Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer’s Disease
title_full_unstemmed Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer’s Disease
title_short Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer’s Disease
title_sort current evidence on the protective effects of recombinant human erythropoietin and its molecular variants against pathological hallmarks of alzheimer’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760199/
https://www.ncbi.nlm.nih.gov/pubmed/33255969
http://dx.doi.org/10.3390/ph13120424
work_keys_str_mv AT jarerobasultojosej currentevidenceontheprotectiveeffectsofrecombinanthumanerythropoietinanditsmolecularvariantsagainstpathologicalhallmarksofalzheimersdisease
AT riveracervantesmarthac currentevidenceontheprotectiveeffectsofrecombinanthumanerythropoietinanditsmolecularvariantsagainstpathologicalhallmarksofalzheimersdisease
AT gascamartinezdeisy currentevidenceontheprotectiveeffectsofrecombinanthumanerythropoietinanditsmolecularvariantsagainstpathologicalhallmarksofalzheimersdisease
AT garciasierrafrancisco currentevidenceontheprotectiveeffectsofrecombinanthumanerythropoietinanditsmolecularvariantsagainstpathologicalhallmarksofalzheimersdisease
AT gascamartinezyadira currentevidenceontheprotectiveeffectsofrecombinanthumanerythropoietinanditsmolecularvariantsagainstpathologicalhallmarksofalzheimersdisease
AT beaszaratecarlos currentevidenceontheprotectiveeffectsofrecombinanthumanerythropoietinanditsmolecularvariantsagainstpathologicalhallmarksofalzheimersdisease